Fundraising Fox
Flavocure Biotech
Baltimore, US · Founded 2018 · Delaware corporation
Find your way into Flavocure Biotech
Sign up to find every way you can get introduced to Flavocure Biotech
- Your email: who you already know at Flavocure Biotech, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Flavocure Biotech team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Flavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
Founders & leadership
NT
Ngeh ToyangNamed on SEC filing
HL
Henry LoweNamed on SEC filing
Board
JG
Justin GrantBoard director
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 rounds · 2022–2025
▶$215KraisedFeb 2025 · 3 investors · BiotechnologyRule 506(b)
▶$215KraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ngeh ToyangExecutive Officer, Director
- Justin GrantDirector
- Henry LoweExecutive Officer, Director
- Douglas LiuExecutive Officer
- Offering amount
- $2M
- Amount sold
- $215K
- Minimum investment
- $25K
- Proceeds to insiders
- $250K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJan 2023 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Swen SimmsPromoter
- Eric ChapmanPromoter
- Ngeh ToyangExecutive Officer, Director
- Henry LoweExecutive Officer, Director
- Douglas LiuExecutive Officer
- David TraylorPromoter
- Justin GrantDirector
- Theresia ToyengPromoter
- Thomas LangExecutive Officer
- David BrooksExecutive Officer
- Anthony DeaseyPromoter
- Saurabh SewakPromoter
- Offering amount
- $1.3M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $168.9K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
NovoCureNovocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
Onkure Therapeutics IncOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Capricor TherapeuticsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Flavocure Biotech.
In the news
Frequently asked questions
- What does Flavocure Biotech do?
- Flavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
- How much funding has Flavocure Biotech raised?
- Flavocure Biotech has disclosed $1.3M raised across 2 rounds.
- Where is Flavocure Biotech headquartered?
- Flavocure Biotech is headquartered in Baltimore, US.